Petrelli N J, Mittelman A
J Surg Oncol. 1984 Mar;25(3):201-6. doi: 10.1002/jso.2930250314.
Five-fluorouracil (5-FU) has become the standard chemotherapeutic agent for the treatment of advanced colorectal carcinoma. It has been used as a single agent and in combination with other chemotherapeutic agents for the treatment of advanced disease. Conflicting experiences have been reported with all these therapeutic programs and a review of these studies reveals failure to take into consideration the factors determining survival and response. These factors consist of performance status, weight loss, hepatomegaly, previous chemotherapy treatment, prior radiotherapy treatment, and resected versus unresected primaries. The purpose of this study is to examine the various claims for therapeutic efficacy of drugs used in all stages of colorectal carcinoma. This will consist of a review of single agent systemic chemotherapy for advanced colorectal carcinoma, combination chemotherapy for advanced colorectal carcinoma, regional infusion, and adjuvant chemotherapy following curative resection.
5-氟尿嘧啶(5-FU)已成为治疗晚期结直肠癌的标准化疗药物。它曾被用作单一药物,也与其他化疗药物联合用于治疗晚期疾病。所有这些治疗方案都有相互矛盾的经验报道,对这些研究的回顾表明,未能考虑到决定生存和反应的因素。这些因素包括体能状态、体重减轻、肝肿大、既往化疗史、既往放疗史以及原发性肿瘤是否切除。本研究的目的是检验用于结直肠癌各阶段的药物的各种治疗效果声明。这将包括对晚期结直肠癌的单药全身化疗、晚期结直肠癌的联合化疗、区域灌注以及根治性切除后的辅助化疗的回顾。